WEBULL
WebtradeDownload

Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Profit Outlook

Simply Wall St · 1d ago

We feel now is a pretty good time to analyse Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) business as it appears the company may be on the cusp of a considerable accomplishment. Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The US$3.2b market-cap company posted a loss in its most recent financial year of US$66m and a latest trailing-twelve-month loss of US$46m shrinking the gap between loss and breakeven. As path to profitability is the topic on Tarsus Pharmaceuticals' investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts’ expectations for the company.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Consensus from 4 of the American Pharmaceuticals analysts is that Tarsus Pharmaceuticals is on the verge of breakeven. They anticipate the company to incur a final loss in 2026, before generating positive profits of US$6.9m in 2027. So, the company is predicted to breakeven just over a year from now. How fast will the company have to grow each year in order to reach the breakeven point by 2027? Working backwards from analyst estimates, it turns out that they expect the company to grow 64% year-on-year, on average, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

earnings-per-share-growth
NasdaqGS:TARS Earnings Per Share Growth October 9th 2026

Given this is a high-level overview, we won’t go into details of Tarsus Pharmaceuticals' upcoming projects, though, keep in mind that generally pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

View our latest analysis for Tarsus Pharmaceuticals

Before we wrap up, there’s one aspect worth mentioning. The company has managed its capital judiciously, with debt making up 21% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

There are too many aspects of Tarsus Pharmaceuticals to cover in one brief article, but the key fundamentals for the company can all be found in one place – Tarsus Pharmaceuticals' company page on Simply Wall St. We've also put together a list of pertinent factors you should further examine:

  1. Valuation: What is Tarsus Pharmaceuticals worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Tarsus Pharmaceuticals is currently mispriced by the market.
  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Tarsus Pharmaceuticals’s board and the CEO’s background.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.